ReviewCirculation2018
Primary Aldosteronism: Practical Approach to Diagnosis and Management.
Review in Circulation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Diagnostic accuracy of adrenal imaging for subtype diagnosis in primary aldosteronism: systematic review and meta-analysis.BMJ open · 2020Pooled it
- Sodium reduction is the key ingredient in dietary treatment of hypertension - a randomized controlled trial on sodium, potassium and nitrate.Journal of human hypertension · 2026Trial
- Online prediction model for primary aldosteronism in patients with hypertension in Chinese population: A two-center retrospective study.Frontiers in endocrinology · 2022Trial
- ACTH Stimulation Maximizes the Accuracy of Peripheral Steroid Profiling in Primary Aldosteronism Subtyping.The Journal of clinical endocrinology and metabolism · 2021Trial
- Clinical outcomes of laparoscopic-based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral aldosterone-producing adenoma.Journal of clinical hypertension (Greenwich, Conn.) · 2020Trial
- Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study.European journal of internal medicine · 2026Article
- Coalescing nephron and ureteric bud progenitors potentiates nephrogenesis in recellularized kidney scaffolds.bioRxiv : the preprint server for biology · 2026Article
- Clinical value of multi-time-pointEndocrine · 2026Article
- Effect of collection timing on selectivity index in unstimulated adrenal venous sampling: discovery and validation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Partially Successful Adrenal Vein Sampling With and Without Cross-Sectional Imaging in Primary Aldosteronism Subtyping.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Article
- Is It Time to Retire Aldosterone Suppression Testing?American journal of hypertension · 2026Review
- High prevalence of primary aldosteronism and its impact on diabetic kidney disease in type 2 diabetes mellitus: A retrospective cohort study.Endocrine · 2026Article
- cAMP/PKA signaling in endocrine hypertension: genetic mechanisms and pathophysiological insights.Frontiers in endocrinology · 2026Review
- Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?Clinical endocrinology · 2025Observational
- Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism.BMC endocrine disorders · 2025Article
- Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease-2025 Update.Nephrology (Carlton, Vic.) · 2025Article
- Primary aldosteronism diagnosis in the intensive care unit: resistant alkalosis and hypokalemia during severe sepsis with hyperlactatemia: a case report.Journal of medical case reports · 2025Article
- MicroRNA-24-3p targeting Top1 in perirenal fat is involved in circulating inflammation and high cardiovascular disease risk in patients with primary aldosteronism.Journal of translational medicine · 2025Article
- Cost-effectiveness analysis of segmental adrenal venous sampling with radiofrequency ablation for primary aldosteronism in Japan.Japanese journal of radiology · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
Primary aldosteronism (PA) is the most common form of secondary hypertension. In many cases, somatic mutations in ion channels and pumps within adrenal cells initiate the pathogenesis of PA, and this mechanism might explain why PA is so common and suggests that milder and evolving forms of PA must exist. Compared with primary hypertension, PA causes more end-organ damage and is associated with excess cardiovascular morbidity, including heart failure, stroke, nonfatal myocardial infarction, and atrial fibrillation. Screening is simple and readily available, and targeted therapy improves blood pressure control and mitigates cardiovascular morbidity. Despite these imperatives, screening rates for PA are low, and mineralocorticoid-receptor antagonists are underused for hypertension treatment. After the evidence for the prevalence of PA and its associated cardiovascular morbidity is summarized, a practical approach to PA screening, referral, and management is described. All physicians who treat hypertension should routinely screen appropriate patients for PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.